Literature DB >> 23704777

Modification of the secretion pattern of proteases, inflammatory mediators, and extracellular matrix proteins by human aortic valve is key in severe aortic stenosis.

Gloria Alvarez-Llamas1, Tatiana Martín-Rojas, Fernando de la Cuesta, Enrique Calvo, Felix Gil-Dones, Veronica M Dardé, Luis F Lopez-Almodovar, Luis R Padial, Juan-Antonio Lopez, Fernando Vivanco, Maria G Barderas.   

Abstract

One of the major challenges in cardiovascular medicine is to identify candidate biomarker proteins. Secretome analysis is particularly relevant in this search as it focuses on a subset of proteins released by a cell or tissue under certain conditions. The sample can be considered as a plasma subproteome and it provides a more direct approximation to the in vivo situation. Degenerative aortic stenosis is the most common worldwide cause of valve replacement. Using a proteomic analysis of the secretome from aortic stenosis valves we could identify candidate markers related to this pathology, which may facilitate early diagnosis and treatment. For this purpose, we have designed a method to validate the origin of secreted proteins, demonstrating their synthesis and release by the tissue and ruling out blood origin. The nLC-MS/MS analysis showed the labeling of 61 proteins, 82% of which incorporated the label in only one group. Western blot and selective reaction monitoring differential analysis, revealed a notable role of the extracellular matrix. Variation in particular proteins such as PEDF, cystatin and clusterin emphasizes the link between aortic stenosis and atherosclerosis. In particular, certain proteins variation in secretome levels correlates well, not only with label incorporation trend (only labeled in aortic stenosis group) but, more importantly, with alterations found in plasma from an independent cohort of samples, pointing to specific candidate markers to follow up in diagnosis, prognosis, and therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23704777      PMCID: PMC3769321          DOI: 10.1074/mcp.M113.027425

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  51 in total

Review 1.  The molecular basis of vascular disorders.

Authors:  J A Towbin; B Casey; J Belmont
Journal:  Am J Hum Genet       Date:  1999-03       Impact factor: 11.025

2.  Vascular tenascin-C regulates cardiac endothelial phenotype and neovascularization.

Authors:  Victoria L T Ballard; Arti Sharma; Inga Duignan; Jacquelyne M Holm; Andrew Chin; Ruby Choi; Katherine A Hajjar; Shing-Chiu Wong; Jay M Edelberg
Journal:  FASEB J       Date:  2006-02-06       Impact factor: 5.191

3.  Gelsolin and cardiac myocyte apoptosis: a new target in the treatment of postinfarction remodeling.

Authors:  Ryosuke Nishio; Akira Matsumori
Journal:  Circ Res       Date:  2009-04-10       Impact factor: 17.367

4.  Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.

Authors:  D W Dawson; O V Volpert; P Gillis; S E Crawford; H Xu; W Benedict; N P Bouck
Journal:  Science       Date:  1999-07-09       Impact factor: 47.728

Review 5.  The biology and pharmacology of PGD2.

Authors:  H Giles; P Leff
Journal:  Prostaglandins       Date:  1988-02

Review 6.  The long pentraxin PTX3 in vascular pathology.

Authors:  Alberto Mantovani; Cecilia Garlanda; Barbara Bottazzi; Giuseppe Peri; Andrea Doni; Yeny Martinez de la Torre; Roberto Latini
Journal:  Vascul Pharmacol       Date:  2006-08-23       Impact factor: 5.773

Review 7.  Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase.

Authors:  Y Urade; O Hayaishi
Journal:  Biochim Biophys Acta       Date:  2000-10-18

8.  Proteomics analysis of human coronary atherosclerotic plaque: a feasibility study of direct tissue proteomics by liquid chromatography and tandem mass spectrometry.

Authors:  Carolina Bagnato; Jaykumar Thumar; Viveka Mayya; Sun-Il Hwang; Henry Zebroski; Kevin P Claffey; Christian Haudenschild; Jimmy K Eng; Deborah H Lundgren; David K Han
Journal:  Mol Cell Proteomics       Date:  2007-03-05       Impact factor: 5.911

Review 9.  Clusterin: physiologic and pathophysiologic considerations.

Authors:  M E Rosenberg; J Silkensen
Journal:  Int J Biochem Cell Biol       Date:  1995-07       Impact factor: 5.085

10.  Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial.

Authors:  Kwan Leung Chan; Koon Teo; Jean G Dumesnil; Andy Ni; James Tam
Journal:  Circulation       Date:  2010-01-04       Impact factor: 29.690

View more
  13 in total

1.  Proteomic Alterations Associated with Biomechanical Dysfunction are Early Processes in the Emilin1 Deficient Mouse Model of Aortic Valve Disease.

Authors:  P M Angel; D A Narmoneva; M K Sewell-Loftin; C Munjal; L Dupuis; B J Landis; A Jegga; C B Kern; W D Merryman; H S Baldwin; G M Bressan; Robert B Hinton
Journal:  Ann Biomed Eng       Date:  2017-08-15       Impact factor: 3.934

Review 2.  Multi-Omics Approaches to Define Calcific Aortic Valve Disease Pathogenesis.

Authors:  Mark C Blaser; Simon Kraler; Thomas F Lüscher; Elena Aikawa
Journal:  Circ Res       Date:  2021-04-29       Impact factor: 17.367

3.  The plasma proteomic signature as a strategic tool for early diagnosis of acute coronary syndrome.

Authors:  Carlos M Laborde; Sergio Alonso-Orgaz; Laura Mourino-Alvarez; José Moreu; Fernando Vivanco; Luis R Padial; María G Barderas
Journal:  Proteome Sci       Date:  2014-10-10       Impact factor: 2.480

Review 4.  Proteomic analysis in cardiovascular research.

Authors:  Teiji Oda; Ken-ichi Matsumoto
Journal:  Surg Today       Date:  2015-04-19       Impact factor: 2.549

5.  iTRAQ proteomic analysis of extracellular matrix remodeling in aortic valve disease.

Authors:  Tatiana Martin-Rojas; Laura Mourino-Alvarez; Sergio Alonso-Orgaz; Esther Rosello-Lleti; Enrique Calvo; Luis Fernando Lopez-Almodovar; Miguel Rivera; Luis R Padial; Juan Antonio Lopez; Fernando de la Cuesta; Maria G Barderas
Journal:  Sci Rep       Date:  2015-12-01       Impact factor: 4.379

6.  Incremental Predictive Value of Longitudinal Axis Strain and Late Gadolinium Enhancement Using Standard CMR Imaging in Patients with Aortic Stenosis.

Authors:  Lucia Agoston-Coldea; Kunal Bheecarry; Carmen Cionca; Cristian Petra; Lelia Strimbu; Camelia Ober; Silvia Lupu; Daniela Fodor; Teodora Mocan
Journal:  J Clin Med       Date:  2019-02-01       Impact factor: 4.241

Review 7.  Dissecting Calcific Aortic Valve Disease-The Role, Etiology, and Drivers of Valvular Fibrosis.

Authors:  Petra Büttner; Lukas Feistner; Philipp Lurz; Holger Thiele; Joshua D Hutcheson; Florian Schlotter
Journal:  Front Cardiovasc Med       Date:  2021-05-10

8.  A clinical perspective on the utility of alpha 1 antichymotrypsin for the early diagnosis of calcific aortic stenosis.

Authors:  Tatiana Martin-Rojas; Laura Mourino-Alvarez; Felix Gil-Dones; Fernando de la Cuesta; Esther Rosello-Lleti; Carlos M Laborde; Miguel Rivera; Luis Fernando Lopez-Almodovar; Juan Antonio Lopez; Finn Akerstrom; Luis R Padial; Maria G Barderas
Journal:  Clin Proteomics       Date:  2017-04-21       Impact factor: 3.988

9.  A comprehensive study of calcific aortic stenosis: from rabbit to human samples.

Authors:  Laura Mourino-Alvarez; Montserrat Baldan-Martin; Tamara Sastre-Oliva; Marta Martin-Lorenzo; Aroa Sanz Maroto; Nerea Corbacho-Alonso; Raul Rincon; Tatiana Martin-Rojas; Luis Fernando Lopez-Almodovar; Gloria Alvarez-Llamas; Fernando Vivanco; Luis Rodriguez Padial; Fernando de la Cuesta; Maria Gonzalez Barderas
Journal:  Dis Model Mech       Date:  2018-06-19       Impact factor: 5.758

Review 10.  Patient Management in Aortic Stenosis: Towards Precision Medicine Through Protein Analysis, Imaging and Diagnostic Tests.

Authors:  Laura Mourino-Alvarez; Tatiana Martin-Rojas; Cecilia Corros-Vicente; Nerea Corbacho-Alonso; Luis R Padial; Jorge Solis; María G Barderas
Journal:  J Clin Med       Date:  2020-07-28       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.